Second-Line Agent for Gastroesophageal Adenocarcinoma Extends Survival

SAN FRANCISCO (IMNG) - A phase III clinical trial of an experimental monoclonal antibody for patients failing first-line treatment of metastatic gastric or gastroesophageal junction adenocarcinoma increased...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news